Zhu Katherine J, Heron Matthew J, Tiongco Rafael Felix P, Biswas Arushi, Weitzner Aidan S, Duclos Olga A, Atayeva Rena, Cooney Carisa M, Cooney Damon S, Broderick Kristen P
From the Department of Plastic & Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Ann Plast Surg. 2025 Apr 1;94(4S Suppl 2):S305-S310. doi: 10.1097/SAP.0000000000004321.
Prepectoral tissue expander (TE) placement is an increasingly used breast reconstruction technique but may have a higher risk for mastectomy skin flap ischemia compared to subpectoral TE placement. Hyperbaric oxygen therapy (HBOT) has been shown to salvage compromised mastectomy skin flaps, but there is limited evidence on which patients require HBOT and benefit most from this treatment.
We retrospectively reviewed patients undergoing immediate TE breast reconstruction over a 6-year period. Patient demographics, intraoperative data, HBOT treatment, complications, and final breast reconstruction type were collected. Analyses were performed by patient and by breast.
Among 348 patients (552 breasts), 299 (86%) patients (477 breasts) had prepectoral and 49 (14%) patients (75 breasts) had subpectoral TE placement. Only prepectoral patients received HBOT (19 patients/33 breasts vs 0 patients/breasts, P = 0.037). Breasts receiving HBOT had higher rates of mastectomy skin necrosis (30-day: 73% vs 5.6%, P < 0.001; 90-day: 76% vs 6.5%, P < 0.001), returns to the OR for necrosis excision (30-day: 18% vs 3.2%, P = 0.001; 90-day: 21% vs 5.4%, P = 0.003), and TE explantation (30-day: 21% vs 1.8%, P < 0.001; 90-day: 24% vs 3.8%, P < 0.00001) at the 30- and 90-day postoperative periods. However, these rates did not significantly increase from 30 to 90 days. For those with mastectomy skin necrosis, HBOT salvaged significantly more mastectomy pockets (76% vs 41%, P < 0.0001).
Patients with prepectoral TE placement were significantly more likely to receive HBOT. Compared to no treatment, HBOT was able to salvage almost twice as many mastectomy pockets, providing valuable information for mastectomy skin flap ischemia treatment options.
胸前组织扩张器(TE)置入是一种越来越常用的乳房重建技术,但与胸肌下TE置入相比,乳房切除术皮瓣缺血风险可能更高。高压氧治疗(HBOT)已被证明可挽救受损的乳房切除术皮瓣,但关于哪些患者需要HBOT以及哪些患者从该治疗中获益最大的证据有限。
我们回顾性分析了6年间接受即刻TE乳房重建的患者。收集患者人口统计学资料、术中数据、HBOT治疗情况、并发症及最终乳房重建类型。按患者及乳房进行分析。
在348例患者(552个乳房)中,299例(86%)患者(477个乳房)采用胸前TE置入,49例(14%)患者(75个乳房)采用胸肌下TE置入。仅胸前TE置入患者接受了HBOT治疗(19例患者/33个乳房 vs 0例患者/0个乳房,P = 0.037)。接受HBOT治疗的乳房在术后30天和90天乳房切除术皮肤坏死发生率更高(30天:73% vs 5.6%,P < 0.001;90天:76% vs 6.5%,P < 0.001),因坏死切除返回手术室的比例更高(30天:18% vs 3.2%,P = 0.001;90天:21% vs 5.4%,P = 0.003),以及TE取出率更高(30天:21% vs 1.8%,P < 0.001;90天:24% vs 3.8%,P < 0.00001)。然而,这些发生率从30天到90天并未显著增加。对于发生乳房切除术皮肤坏死的患者,HBOT挽救的乳房切除腔隙显著更多(76% vs 41%,P < 0.0001)。
胸前TE置入患者接受HBOT治疗的可能性显著更高。与未治疗相比,HBOT能够挽救的乳房切除腔隙几乎多一倍,为乳房切除术皮瓣缺血的治疗选择提供了有价值的信息。